# Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia

> **NCT01905436** · — · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 21862 (actual)

## Conditions studied

- Lymphatic Filariasis
- Onchocerciasis
- Soil Transmitted Helminth (STH) Infections

## Interventions

- **DRUG:** Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration

## Key facts

- **NCT ID:** NCT01905436
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2017-04
- **Final completion:** 2021-07
- **Target enrollment:** 21862 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01905436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01905436, "Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01905436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*